NCT07903376

A First-in-Human, Open-Label, Single-Center Study to Evaluate the Safety, and Tolerability of SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE)

Study Summary

The goal of this clinical trial is to learn about the safety, and tolerability of giving an experimental gene therapy called SPX-01 to an infant with spinal muscular atrophy (SMA) type 1. SMA type 1 is a rare inherited disease that causes severe muscle weakness and can affect breathing, swallowing, and movement. SPX-01 is designed to deliver a working copy of a gene called SMN1, which does not function properly in children with SMA. The main questions this study aims to answer are: * What side effects or medical problems occur after SPX-01 is given? * What changes in the infant's movement, breathing, and overall health are observed during follow-up? One infant aged 6 months or younger with genetically confirmed SMA type 1 will take part in this study. The infant will: * Receive a single dose of SPX-01 through a vein over approximately one hour. * Attend follow-up visits over 12 months, including medical examinations, blood tests, and assessments of movement and breathing.

Interested in this trial?

Submit an Inquiry

Interventions

SPX-01GENETIC
SPX-01 is an investigational self-complementary AAV9 gene therapy vector containing a functional, codon-optimized human SMN1 transgene under the control of the CAG promoter. A single intravenous dose of 1.1 × 10\^14 vector genomes/kg body weight. Oral prednisolone at 1 mg/kg/day will be initiated approximately 24 hours before infusion and continued for an initial 30-day treatment period. Subsequent tapering over at least 28 days will be performed only when protocol-specified clinical and laboratory criteria are met. Corticosteroid therapy may be extended in the presence of persistent liver abnormalities.

Study Locations

FacilityCityStateCountry
Children's Medical CenterTehranTehran ProvinceIran

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: November 22, 2026